Color Health
Founded 2013 · CIK 0001683327 · Medtech · Private
Population-scale genomic testing and cancer screening platform
color.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $263M
- 4 Form D · Nov 2021
- 59 months since last filing
- Contracts
- $2.4M
- 4 awards · Veterans Affairs, Health and Human S
- #197 of 4531 in medtech
- Patents
- 12
- 9 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $38,548,112 | |
| Federal contract | Department of Veterans Affairs · Idiq Contract For Dna Collection Kits And Testing. | $12,948 | |
| Private capital raised | Form D · SEC | $51,989,862 | |
| Federal contract | Department of Veterans Affairs · Idiq Contract For Dna Collection Kits And Testing. | $12,689 | |
| Federal contract | Department of Veterans Affairs · Hereditary Cancer Test Kits, Testing And Counseling For Puget Sound Vamc R&d | $64,738 | |
| Private capital raised | Form D · SEC | $127,224,203 | |
| Private capital raised | Form D · SEC | $45,690,932 | |
| Federal contract | Department of Health and Human Services · Icatt | $2,283,208 |
Federal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 194 | SPATIAL SURGICAL LLC | $2.4M | — |
| 195 | BOSTON CELL STANDARDS INC. | $2.4M | — |
| 196 | EMITECH, INC. | $2.4M | — |
| 197 | Color Health | $2.4M | $263M |
| 198 | DOSEOPTICS LLC | $2.4M | — |
| 199 | BIONIC SKINS LLC | $2.4M | — |
| 200 | FERRO SOLUTIONS, INC. | $2.3M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sherwin ChenExecutive Officer
- Gil EladDirector
- Elad GilDirector · Executive Officer
- Taneja HemantDirector
- Michael HerringExecutive Officer
- Othman LarakiDirector · Executive Officer
- Hemant TanejaDirector
- Susan WagnerDirector
Patents
- Systems And Methods For Enhanced User Specific Predictions Using Machine Learning Techniquesgranted
- Variant Identification By Unique Data Set Detectiongranted
- Methods For Depletion Of High-copy Sequences In Multiplexed Whole Genome Sequencing Librariesapplication
- Methods For Depletion Of High-copy Sequences In Multiplexed Whole Genome Sequencing Librariesgranted
- Communication Generation Using Sparse Indicators And Sensor Dataapplication
- Communication Generation Using Sparse Indicators And Sensor Datagranted
- Variant Identification By Unique Data Set Detectiongranted
- Communication Generation Using Sparse Indicators And Sensor Datagranted
- Methods For Depletion Of High-copy Sequences In Multiplexed Whole Genome Sequencing Librariesgranted
- Communication Generation Using Sparse Indicators And Sensor Datagranted
- Communication Generation Using Sparse Indicators And Sensor Datagranted
- Applying Low Coverage Whole Genome Sequencing For Intelligent Genomic Routingapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.